Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | UCHL1 | P09936 | 6/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30955281 | 1.00 | HDAC1 (0.53) | HDAC1HDAC6UCHL1NOTUMUSP30 | |
| SCHEMBL22048927 | 0.93 | HDAC1 (0.51) | HDAC1HDAC6UCHL1NOTUMUSP30 | |
| SCHEMBL7428221 | 0.87 | UCHL1 (0.50) | HDAC1HDAC6UCHL1NOTUMAR | |
| SCHEMBL30955266 | 0.87 | NOTUM (0.50) | HDAC1HDAC6UCHL1NOTUMKDM1A | |
| SCHEMBL27438071 | 0.87 | NOTUM (0.50) | HDAC1HDAC6UCHL1NOTUMKDM1A | |
| SCHEMBL30832851 | 0.87 | UCHL1 (0.50) | HDAC1HDAC6UCHL1NOTUMAR | |
| SCHEMBL30955214 | 0.83 | UCHL1 (0.45) | HDAC1HDAC6UCHL1NOTUMKDM1A | |
| SCHEMBL27438069 | 0.83 | UCHL1 (0.45) | HDAC1HDAC6UCHL1NOTUMKDM1A | |
| SCHEMBL28834876 | 0.82 | NOTUM (0.65) | NOTUMARMYC | |
| SCHEMBL23063791 | 0.81 | NOTUM (0.64) | HDAC1HDAC6UCHL1NOTUMKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2016025933-A2 | SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| EP-2516439-B1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| US-8530648-B2 | Diaza-spiro[5.5]undecanes | NOVARTIS AG (CH) | 2013-09-10 | — | — | US | disclosed |
| EP-2516439-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076747-A1 | DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264748-A1 | DIAZA-SPIRO[5.5]UNDECANES | REN, PKD1, NR3C2 | HDAC1 616/4885HDAC6 337/4885UCHL1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.